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Absorption and disposition of furosemide in congestive heart failure.
Changes in response to furosemide and other diuretics in patients with
congestive heart failure (CHF) could occur because of disease-induced
changes in absorption of the drug or changes in disposition which affect
its access to its site of action. A difference was not found in the
bioavailability of furosemide in patients with CHF compared to normal
volunteers, 31 12 vs. 38 20% (mean SD), respectively. Both
groups showed considerable interindividual variability, though serial
analyses within individuals revealed consistency. Amounts of furose-
mide delivered into the urine after an intravenous dose correlated
significantly to that after an oral dose implying that the interindividual
variability is not caused primarily by variability in absorption in either
group. Overall, disposition kinetics of furosemide did not differ between
groups. Because of heterogeneity of renal and cardiac function among
the patients, we were able to demonstrate correlations of plasma and
renal clearance of furosemide with renal function; in turn, renal function
correlated with left ventricular ejection fraction. Consequently, some
patients had changes in furosemide disposition, but, for the most part,
differences in response to furosemide were caused by abnormal re-
sponses to, rather than changed handling of the diuretic.
Absorption et disponibilité du furosémide au cours de I'insuffisance
cardiaque congestive. Des modifications de Ia réponse au furosémide et
a d'autres diuretiques chez des malades ayant une insuffisance cardi-
aque congestive (CHF) pouvaient se produire en raison de modifica-
tions de l'absorption du médicament induites par Ia maladie, ou de
modifications de sa disponibilité, modifiant son accession a ses sites
d'action. La difference n'étC pas trouvé dans la biodisponibilite du
furosémide chez des malades ayant une CHF par rapport a des
volontaires normaux, 31 12 contre 38 20% (moyenne su),
respectivement. Dans les deux groupes, ii existait tine variabilité
interindividuelle considerable, mais les analyses sériées par individu
indiquaient une certaine constance. Les quantités de furosémide appar-
aissant darts l'urine après administration intraveineuse étaient significa-
tivement corrélées aux quantités apparaissant après prise orale, ce qui
indique que Ia variation interindividuelle n'est pas primitivement due a
des differences d'absorption dans l'un ou l'autre groupe. D'une facon
generale, Ia pharmacocinetique du furosémide n'était pas différente
entre les deux groupes. En raison de l'heterogéneité des fonctions
rénale et cardiaque des malades, nous avons pu mettre en evidence des
correlations entre Ic furosémide plasmatique et Ia clearance rénale du
furosémide avec Ia fonction renale; la fonction rénale Ctait elle-même
corrélée avec Ia fraction d'djection ventriculaire gauche. En consé-
quence, si quelques malades avaient des modifications de Ia disponibi-
lité du furosémide, mais chez la plupart d'entre eux, les differences de
réponse au furosemide étaient dues a une réponse anormale au diuré-
tique, plus qu'à une modification de sa pharmacocinetique.
and subnormal responses commonly occur with occasional
patients manifesting a refractory state. In patients with azote-
mia, decreased furosemide elimination correlates with the de-
gree of renal dysfunction [1—3]. This decreased elimination is
not only due to decreased nephron mass but also to the
inhibition of furosemide secretion into the lumen of the proxi-
mal tubule by accumulated endogenous organic acids [4—6].
This altered disposition of furosemide in azotemia correlates
with decreased diuretic response; which, in turn, correlates
with decreased delivery of furosemide into the urine. In pa-
tients with CHF, the influence of myocardial dysfunction on the
absorption and subsequent disposition of furosemide as a
potential mechanism of diuretic resistance has been little ex-
plored. Previous investigators have suggested that CHF might
affect the absorption of furosemide and observed a large vari-
ability in absorption in normal subjects and in patients with
CHF [7]. Others have demonstrated increased serum concen-
trations and prolongation of the serum half-life in patients with
CHF after intravenous administration of furosemide [81. Rela-
tionships between indices of cardiac performance and furose-
mide disposition have not been reported. Understanding the
changes in drug disposition caused by disease states might
provide a more rational approach to the treatment of patients in
whom resistance to the drug occurs. We performed this study to
assess absorption and disposition of furosemide in patients with
a broad spectrum of severity of congestive heart failure.
Methods
Subjects. The protocol for these studies was approved by the
Committee on Human Experimentation at the University of
Texas Health Science Center at Dallas. Each subject signed an
informed consent for the study after explanation of the proce-
dures. No adverse effects occurred.
Normal volunteers. For comparisons to patients with conges-
tive heart failure, we studied 32 normal volunteers. In eight of
these subjects, detailed pharmacokinetic analyses were per-
formed and have been reported previously [9, 10]. Earlier
The potent diuretic, furosemide, is used frequently to treat
patients with congestive heart failure (CHF) and other edema-
tous states. In these settings the diuretic response is variable,
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studies of bioavailability of furosemide have showed great
variability. Consequently, we wished to assess bioavailability in
a greater number of subjects, and in an additional 17 volunteers
paired studies of orally and intravenously administered furose-
mide were performed to provide bioavailability data in a total of
25 subjects. We also studied seven subjects after oral adminis-
tration alone. In the first eight subjects, we sampled blood and
urine serially; in the latter 24 subjects, total 24-hr urine samples
were collected after the administration of furosemide. The
subjects receiving both dosage forms were studied in random
order, and at least 1 week elapsed between studies.
Patients with congestive heart failure. We studied 25 patients
with CHF, hospitalized on the Internal Medicine Service of
Parkland Memorial Hospital. Each patient was stable, a clinical
assessment made by ourselves and housestaff. Six patients had
peripheral edema at the time of the study. Two patients, 6 and
9, had regurgitation lesions in mitral and aortic valves. These
patients had been hospitalized for varying periods of time. Each
had been admitted for control of newly diagnosed or worsening
CHF (usually secondary to poor compliance with diet or
therapeutic regimen). They were receiving stable doses of
digitalis and furosemide and were neither gaining or losing
weight at the time of study. They were maintained on diets
containing a sodium intake ranging from 50 to 150 mEqlday. In
summary, these patients had been treated and stabilized and
were studied during a state deemed suitable for their discharge
from the hospital. Our data, therefore, may not be extrapolable
to the acutely decompensated patient or the patient refractory
to large parenteral doses of furosemide.
For complete pharmacokinetic studies in 16 patients, we
administered 40 mg of furosemide via an indwelling intravenous
catheter and collected serial blood and urine specimens. These
patients were "resistant" to furosemide. Evaluation of "dose-
response" curves relating urinary furosemide to sodium excre-
tion (not shown) were shifted downward and to the right in
patients with CHF. Similarly, 24-hr urinary sodium excretion
(mean SD) in these patients administered furosemide was
158.4 122.5 vs. 289,6 52.0 mEq in normals (P = 0.008). In a
24-hr urine specimen collected the day prior to study while
patients were receiving no diuretics, the sodium content was
74.9 14.4 and 131.0 51.8 mEq for patients and normal
controls, respectively. Though sodium restriction per se can
decrease response to diuretics, the moderate sodium restriction
in these patients reflected by their basal sodium excretion rates
is unlikely to have accounted for their subnormal response. In
an additional nine patients, furosemide was administered either
orally or intravenously with collection of a 24-hr urine sample.
Patients remained recumbent except to void. Left ventricular
ejection fraction was determined by gated blood pooi scintigra-
phy [11]. Beginning the morning of the second day, seven of
these patients were administered 40 mg of oral furosemide
daily. We collected 24-hr urine samples in these patients for two
to six consecutive days.
Laboratory determinations. Serum and urine samples were
measured for furosemide. sodium, potassium, and creatinine.
Furosemide was measured by HPLC as previously described
19, 10]. This assay has recently been confirmed to be highly
specific 1121, Sodium and potassium were measured with an
Instrumentation Laboratory Model 143 flame photometer and
creatinine with a Technicon Autoanalyzer.
Data analysis. Pharmacokinetic analyses were performed in
16 patients in whom we completed serial collections of serum
samples. Each set of data from individual patients was fit to an
exponential equation of the form:
= Aet + Bet
where C, equals serum concentration of furosemide at time t; A
and B are hybrid constants; and a and /3 are hybrid rate
constants of fast and slow components of disposition, respec-
tively. We utilized the CSTRIP computer program to obtain
initial parameter estimates, and the NONLIN computer pro-
gram for final estimation of the parameters [13, 141. The
weighting function of the fit was l/C or l/C2 and the goodness
of fit was assured by examining residuals, visual inspection of
the fit, and R2 [15]. The pharmacokinetic parameters for each
patient were calculated from equations described by Wagner
[16], that is, Cl1, = Dose/AUC0,; Vdarea or Vd Dose//3(AUC0); and Vd = Dose x (A/a2 + B//32)I(AUCç,)2
where Cl1, = plasma clearance, Vd = volume of distribution at
steady state, Vdarea or Vd = apparent volume of distribution
calculated by the area under the curve, and AUC. = area
under the curve calculated from the integral of the plasma
concentration versus time from zero to infinity. The renal
clearance, Clr, for each patient was determined usually by the
linear regression slope of the urinary furosemide excretion rate
against the serum concentration of furosemide at the midpoint
of the urine collection. The intercepts of these regression lines
did not differ from zero and were forced through zero. In a few
patients renal clearance was calculated as the total amount of
drug recovered in the urine divided by the serum A1,JC. The
pharmacokinetic parameters of eight normal volunteers previ-
ously reported by us were used for comparison to this patient
population [9, 10]. We also analyzed all the individual data
using the noncompartmental method of Benet and Galeazzi
[17]. Values using this method were virtually the same as those
derived using compartmental analysis; we have elected to
present the data generated by the latter approach.
Correlations within groups were tested parametrically by
linear regression or nonparametrically using the Spearman Rho
rank correlation. Significance of differences between groups
was tested by Student's t test.
Results
The patients in whom complete pharmacokinetic evaluation
was performed represented a spectrum of degrees of impaired
left ventricular function with left ventricular ejection fractions
(LVEF) ranging from 0.08 to 0.64 with a mean of 0.32. These
patients showed varying degrees of moderate renal impairment
with creatinine clearance ranging from 19 to 133 mI/mm/I .73
m2.
Effect of congestive heart failure on absorption or hioa vail-
ability offuroseinide. Table 1 depicts total amounts of urinary
furosemide after oral and after intravenous administration of a
40-mg dose plus the ratio of the two in the same individual. This
ratio is a measure of bioavailability and did not differ between
groups. However, patients with CHF delivered less drug into
the urine after both dosing routes compared to normal subjects.
This difference most likely occurred because of decreased renal
function with concomitant lower renal clearance of furosemide
in some of these patients (vide infra). There is large variability
Oral dose IV. dose Ratio
rng/24 hr mg/24 hr P.O./I.V.Subjects N
Normal 25
7
23.08
(13.8 —
6.37
38.3 )
0.38 + 0.20
(0.11 — 0.79)
CHF 13
7
17.32 ÷
7.6 —
7.99
32.4 )
0.31 0.12
(0.13 0.57)
P value
16.12 8.79
6.0 — 30.1
0.039 0.021
)
0.256
a Values in parentheses denote range.
Statistical comparisons are made between groups only in patients receiving both oral and intravenous doses. Additional data are shown to
demonstrate consistency of the findings.
9.17 5.95
(1.8 — 23.6
5.94 1.14(4.3 — 7.2
5.38 + 3.05
(1.5 — 10.4
5.91 2.23
(2.9 — 10.0
of urinary furosemide in both normal subjects and patients with
CHF. However, the intraindividual variability is considerably
smaller as indicated by a relatively smaller day-to-day variation
in each patient with CHF when urinary furosemide was deter-
mined on serial daily urine collections for up to 6 days (Table 2).
The relationship in the same individual between urinary
furosemide after intravenous and oral administration is depicted
in Figure 1 for both normals and patients with CHF. Both
groups demonstrated significant correlations: r -= 0.642, P =
0.008, and r = 0.791, P = 0.001, respectively. In other words,
individuals, either patients or normal volunteers, who excreted
small amounts of furosemide after intravenous dosing also
excreted small amounts after oral dosing, and the converse. The
linear regression of the data from the two groups did not differ
statistically.
In summary, patients with CHF differed from normal sub-
jects in the total amount of drug delivered into the urine after
both routes of administration. The ratio of drug delivered after
oral and intravenous dosing, a measure of bioavailability, was
no different. Each group showed considerable variability. The
significant relationship between urinary furosemide after intra-
venous and oral dosing indicates that this variability is, at least
in part, related to factors other than absorption (including first
pass effect) and may imply a role of intrinsic interindividual
differences in the contribution of nonrenal pathways of elimina-
tion to overall clearance of the drug.
Effect of CHF on disposition of furosemide. After intrave-
nous administration of furosemide, the serum concentration
versus time curve followed a two-compartment model for all
patients and normal subjects. The urinary furosemide excretion
rate and urinary sodium excretion rate declined parallel to the
serum concentration. Figure 2 depicts examples of data of two
patients (5 and 7) for serum concentration, furosemide excre-
tion rate, and sodium excretion rate versus time. Table 3
presents pharmacokinetic parameters of the 16 patients. As a
group, the patients with CHF did not differ from normal
subjects. However, the group of patients with CHF consisted of
patients with a range of renal and cardiac function. The serum
and renal clearance and elimination rate constant correlated
with creatinine clearance (Fig. 3). Serum half-life appeared to
follow a curvilinear relationship with creatinine clearance as
one would predict (Fig. 3). Also, as one might have predicted,
the elimination rate constant correlated with both serum and
renal clearances of furosemide (P < 0.01). Left ventricular
ejection fraction correlated with creatinine clearance (r = 0.590)
(P < 0.05) implying the renal dysfunction was at least, in part, a
manifestation of the severity of cardiac disease. Decrements in
renal function, in turn, resulted in decreased total and renal
clearance of furosemide and diminished drug in the urine after
either route of administration. Changes in handling of furose-
mide in patients with CHF, therefore, appear mainly to be
dependent upon renal function.
Discussion
Theoretically, a reduced diuretic response in some patients
with CHF could occur by decreased oral absorption with/or
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Table 1. Twenty-four-hour urinary furosemide excretion relative to a 40-mg dose in patients with congestive heart failure (CHF) and normal
subjects (mean SD)a
3.56
2.31
4.83
1.18
4.17
2.82
Table 2. Sequential 24-hr urinary furosemide excretion after 40 mg dosing in patients with congestive heart failure
Oral administration, mg
- — IV. administration
Patients Day I Day 2 Day 3 Day 4 Day 5 Day 6 Mean so mg
13.36 7.29 6.53 3.59 13.10
2 1.53 3.15 3.40 1.79 13.62
3 2.93 4.40 4.05 1.00 20.3
4 2.14 1.14 1.48±0.57 11.3
5 8.62 13.22 10.40 2.47 32.45
6 5.37 6.70 6.07 0.67 21.29
7 2.24 3.11 2.67 0.62 11.06
5.66
3.92
9.36
5.11
6.68
6.14
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decreased urinary excretion of furosemide [181. Overall, pa-
tients with CHF in this study did not differ from normal subjects
in bioavailability of furosemide; however, delivery of drug to
the urinary site of action after both oral and intravenous
administration was decreased. I
:The ratio of urinary furosemide after oral to that after
intravenous administration is a measure of bio-availability. In
. . .this study therefore blo-availability in patients with CHF did
not differ from that of normal subjects, consistent with the data
reviewed by Benet [19] and by Cutler and Blair [201. In spite of
theoretical postulates that patients with CHF may have edema,
decreased perfusion, or changed motility of the gastrointestinal
tract, all of which could affect absorption, this study provided
no evidence for differences in extent of absorption of furose-
mide in patients compared to normal subjects. However, both
groups demonstrated considerable interindividual variability of
furosemide excretion into urine after both routes of administra-
tion while consistency within an individual was maintained.
Interindividual variability in absorption, renal or nonrenal
clearance could account for these findings. Our demonstration
of the close correlation of furosemide delivery into the urine
after oral compared to intravenous dosing implies that variahili-
ty in absorption among individuals was not a major factor in the
present study. Consequently, intrinsic differences in nonrenal
and renal clearances were more likely causes of this interindivi-
dual variability. These data emphasize that nonrenal excretion
of furosemide is also a major route of elimination and contrib-
utes importantly to its disposition.
Patients with CHF delivered less total drug into the urine
than did normal subjects. This appears to have been a function
of decreased renal and total clearance of furosemide, probably
caused by decreased overall renal function which, in turn,
appeared to be related to the severity of heart disease. It is
likely that some of these patients also may have had a compo-
nent of intrinsic renal disease. It is evident in patients with CHF
comparable to those in this study that one would predict
differences from normal subjects in handling of furosemide
mainly when renal function is compromised, and even then,
changes appear to be slight.
.
Fig. 2. Representative data of two individual patients, no.5 (left panel)
.
.
. .and no. 7 (right panel) showing serum concentration of furose,n,de(Cp), urinary fitrosemide excretion rate (UF), and urinary sodium
excretion (UNA) rare versus time (top to bottom panels, respectively).
Andreason and Mikkelsen studied the distribution and elimi-
nation of furosemide in patients with CHF compared to normal
subjects and demonstrated that the plasma clearance
significantly lower in patients than in normals, 1.23 vs. 2.34
kg/mm, respectively 18]. The volume of distribution at steady
state (Vd) did not differ significantly, 0.140 liter/kg and 0.181
liter/kg for the patients with CHF and the normal subjects,
respectively. These pharmacokinetic parameters are similar
those of our study as well as more limited studies of other
investigators. Tilstone and Lawson reported in abstract form
that a lower volume of distribution of the central compartment
and a lower plasma clearance of furosemide occurred in patients
with CHF [21]. In the recent study by Perez, Sitar, and Ogilvie
apparent volume of distribution varied greatly among patients
with acute pulmonary edema ranging from 0.085 to 0.818 liter!
kg with a median of 0.353 liter/kg [22]. Our findings of
correlation of plasma and renal clearance of furosemide with
renal function which, in turn, correlated with cardiac function
support the impression that the large variability reported
different studies is, in part, caused by studying patients with
various degrees of cardiac and renal impairment. The correla-
tion of plasma and renal clearance of furosemide with creatinine
clearance is expected because furosemide is secreted by
proximal tubule, the capacity of which decreases with
creased renal mass and/or decreased perfusion to a normal
nephron mass 123, 24]. Studies in patients with renal failure
.
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Table 3. Pharmacokinetic parameters of furosemide (40 mg) in patients with congestive heart failure compared to eight normal volunteers
tlI2 t1120 Vd Vdas
1/kg
Cl Cir Clar LVEF
%
0Cr
ml/min/1.73 m2Patient mm mi/mm/kg
1 14
6 11
4 22
5 5
3 Il
7 6
8 24
9 10
10 65
11 42
12 8
13 15
14 26
15 17
16 14
17 23
82
50
119
78
108
154
127
99
327
173
116
92
103
134
57
129
0.122
0.413
0.119
0.105
0.127
0.134
0.194
0.315
0.254
0.346
0.127
0.207
0.206
0.176
0.160
0.172
0.097
0.353
0.089
0.084
0.089
0.076
0.125
0.148
0.216
0.227
0.114
0.102
0.131
0.169
0.130
0.144
1.03
5.71
0.70
0.93
0.81
0.60
1.06
2.20
0.54
1.39
0.75
1.56
1.38
0.91
1.93
0.93
0.34
2.83
0.20
0.73
0.35
0.14
0.63
1.11
0.14
0.09
0.13
0.37
0.55
0.07
1.20
0.16
0.69
2.88
0.50
0.20
0.46
0.46
0.43
1.09
0.40
1.30
0.62
1.19
0.83
0.84
0.73
0.77
22
38
55
28
62
29
64
63
14
16
15
45
10
2!
20
8
81
75
72
90
46
23
99
106
19
43
38
133
75
28
44
42
Mean 20
SD
122 0.198 0.143 1.40 0.56 0.84
Normal subjects (N = 8)
Mean 17
SD
91 0.351 0.161 1.84
1.02
1.05 0.80
P value 0.585 0.206 0.103 0.682 0.396 0.112 0.875
patients, detecting small differences between groups becomes
14 difficult and would require a large number of subjects. Conse-
' quently, though our study groups were rather large for this type
10 > of study, the risk of a beta-type (false negative) error remains.
Our goal was to assess patients with a broad spectrum of
6 E severity of cardiac disease. Though, in toto this group of
d' patients did not differ from normal subjects in a number of
2 variables measured, it is entirely possible that certain sub-
groups of patients may well have differed. Indeed, our demon-
220 stration of correlations of indices of disease severity with
disposition of furosemide supports this possibility. Further
180 studies are needed in subgroups of patients such as those
"refractory" to furosemide or those "resistant" but at end-
140 stage cardiac disease with uniformly very low LVEF's. Our
data should be viewed most pertinent to the "average" patient
100 with CHF.
Though, overall, only minor changes in handling of furose-
60 mide occurred in our patients with CHF, some individual
patients may have sufficiently low absorption (either intrinsic or
20 secondary to cardiac effects) and/or changed disposition such
that their altered response is due to changed pharmacokinetics
of furosemide [25]. However, for the most part, it appears that
the resistance to furosemide in patients with CHF such as those
in this study manifests as a change in the pharmacodynamics of
response, the mechanisms of which are related undoubtedly to
the pathophysiology of altered solute homeostasis in the disease
[26]. The therapeutic implications of this study are unclear. For
the unusual patient with abnormal handling of furosemide, a
greater dose or administering the dose by vein might be
appropriate. Patients with abnormal dynamics of response,
however, would be more dependent on reversing pathophysio-
logic events in the kidney to manifest a response with incre-
1.4
1.0
0.6
0.2 _
2.83. r 0.710
P<0.01
S
S
.
SS
. S •
'S
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IS •
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-
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C)
0.2
5.71
:.•°
•327
Tt.
14020 60 100 140 20 60 100
Creatinine clearance, mI/mIn/1.73 m2
Fig. 3. Relationship between renal function and furosemide pharmaco-
kinetics in patients with congestive heart failure. Spearman r values (r)
and their significance are shown in the figure.
have demonstrated a similar relationship of renal and plasma
clearance to renal function [1, 2].
It is important to point out limitations of our data. Because of
the large interindividual variability among normal subjects and
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ments in dose achieving little except subjecting the patient to
potentially toxic amounts of drugs.
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